Biosimilars in rheumatology: understanding the rigor of their development (Q26744773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

review article

4 references

15 August 2020

14 November 2020

1 May 2021

Biosimilars in rheumatology: understanding the rigor of their development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

disease-modifying antirheumatic drug

3 April 2020

main subject

2 references

PubMed publication ID

14 November 2020

2 references

PubMed publication ID

1 May 2021

1 reference

15 August 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Kamali Chance

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

30 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 February 2017

3 references

15 August 2020

14 November 2020

1 May 2021

5 references

17 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

15 August 2020

14 November 2020

1 May 2021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

187-197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

3 April 2020

4 references

17 June 2019

15 August 2020

14 November 2020

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 May 2021

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

26 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

On the regulatory approval pathway of biosimilar products

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Gaucher disease: clinical profile and therapeutic developments

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5410928

Disability in rheumatoid arthritis in the era of biological treatments

28 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

Inequities in access to biologic and synthetic DMARDs across 46 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEW206

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

21 January 2018

1 reference

12 December 2020

The state of the art in the development of biosimilars

1 reference

12 December 2020

Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases

1 reference

12 December 2020

International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice

1 reference

12 December 2020

10.1093/RHEUMATOLOGY/KEW206

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

27241704

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27241704%20AND%20SRC:MED&resulttype=core&format=json